+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gynecology Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 115 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4987011
UP TO OFF until Jun 30th 2023

The gynecological drugs market studied was anticipated to grow with a CAGR of nearly 5.6% during the forecast period. The major factors attributing to the growth of the market are significant changes in lifestyle which contributed to a steep rise in the number of gynecological disorders and gynecology cancer. For instance, according to the World Health Organization in 2018, cervical cancer is the fourth most common type of cancer that occurs in women. In 2018, WHO estimated 570, 000 women in the world were diagnosed with cervical cancer worldwide, and about 311, 000 women died from the same in that year. The rising incidence of various gynecological cancer is projected to be continued in the future which is likely to fuel the demand for efficient treatment driving the global gynecological drugs market throughout the forecast period.

Key Market Trends

Non-hormonal Therapy Segment is Expected to Hold the Major Market Share in the Gynecology Drugs Market

  • The non-hormonal therapy segment is expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment, rapid advancements in new product development with reduced side effects coupled with the availability of a wide range of marketed products. Furthermore, the disadvantages of hormonal therapy such as the risk of breast cancers, other complications associated with these products are expected to foster the demand for non-hormonal products during the forecast period.
  • Based on Distribution Channel, hospital pharmacies account for the highest revenue in the market due to increased preference for the patients owing to the prevalence of hospital-associated cases in recent years. Furthermore, increased access to specialty care products, pathological products, and clinical examinations, diagnosis of the gynecological ailments at a single premise are best possible in hospitals indicate an exponential growth of the segment. On the other hand, online pharmacies are anticipated to witness the highest CAGR during the forecast period owing to rising adoption among the women due to increased access to the these online pharmacies along with rise in preference for online consulting, payments, and availability of wide range of products online which is likely to boost the growth of global gynecology drugs market in the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the global gynecological drugs market throughout the forecast period. This dominance is mainly owing to rising incidences of breast cancer, menopausal disorders, polycystic ovary syndrome, and others due to busy lifestyles and the rise in stress among the women in the United States region which registers the highest revenue in the region. For instance, according to the Centers for Disease Control and Prevention CDC report published in 2019, PCOS affects around 6% to 12% representing more than 5 million women of reproductive age and was identified as one of the most common causes of female infertility in the United States is also fueling the market. Moreover, the availability of advanced healthcare infrastructure, increase in government expenditure for the women healthcare awareness, geriatric women population along with early product launches with enhanced quality in the region are expected to contribute its outstanding share in the growth of global market revenue over the forecast period.

Competitive Landscape

The global gynecological drugs market is moderately competitive and consists of several major players. Some prominent players in the market are implementing various strategies such as launching new products and making acquisitions to consolidate their market positions across the globe. Furthermore, a steep rise in the availability of public fundings for the development of these drugs due to a rise in global burden is also expected to fuel the market. For instance, in December 2019, Allergan announced that its product PrFIBRISTAL was publicly funded through the Ontario Drug Benefit (ODB) Formulary, Alberta Drug Benefit List (ADBL), Saskatchewan Formulary and the Non-Insured Health Benefits (NIHB) Program. PrFIBRISTAL is used in first-in-class medical treatment for uterine fibroids, the most common gynecological tumor which affects almost one-in-three Canadian women of reproductive age and a leading cause of surgeries which is likely to create more opportunities in the market during the forecast period. Some of the companies which are currently dominating the market are Allergan Plc, Pfizer Inc, AbbVie Inc, TherapeuticsMD Inc, and Ferring Holding SA.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Burden of Gynecological Diseases
4.2.2 Rise in Healthcare Awareness along with Increasing Ageing Female Population
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework that Delays the Approval of Products
4.3.2 High Cost
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Therapeutics
5.1.1 Hormonal Therapy
5.1.2 Non-hormonal Therapy
5.2 By Indication
5.2.1 Gynecology Cancers
5.2.2 Menopausal Disorder
5.2.3 Polycystic Ovary Syndrome
5.2.4 Contraception
5.2.5 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Pfizer Inv
6.1.2 AbbVie Inc
6.1.3 TherapeuticsMD Inc
6.1.4 Ferring Holding SA
6.1.5 Lupin Pharmaceuticals Inc
6.1.6 Johnson & Johnson
6.1.7 Eli Lilly and Company
6.1.8 Bayer AG

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer Inv
  • AbbVie Inc
  • TherapeuticsMD Inc
  • Ferring Holding SA
  • Lupin Pharmaceuticals Inc
  • Johnson & Johnson
  • Eli Lilly and Company
  • Bayer AG